亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

病毒释放 医学 不利影响 中和抗体 病毒学 毒性 内科学 胃肠病学 病毒 免疫学
作者
Kristopher J. Kimball,Meredith A. Preuss,Mack N. Barnes,Minghui Wang,Gene P. Siegal,Wen Wan,Hui‐Chien Kuo,Souheil Saddekni,Cecil R. Stockard,William E. Grizzle,Raymond D. Harris,Rosemarie Aurigemma,David T. Curiel,Ronald D. Alvarez
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:16 (21): 5277-5287 被引量:104
标识
DOI:10.1158/1078-0432.ccr-10-0791
摘要

Abstract Purpose: To determine the maximum tolerated dose (MTD), toxicity spectrum, clinical activity, and biological effects of the tropism-modified, infectivity-enhanced conditionally replicative adenovirus (CRAd), Ad5–Δ24–Arg-Gly-Asp (RGD), in patients with malignant gynecologic diseases. Experimental Design: Cohorts of eligible patients were treated daily for 3 days through an i.p. catheter. Vector doses ranged from 1 × 109 to 1 × 1012 viral particles per day. Toxicity was evaluated using CTCv3.0. CA-125 and Response Evaluation Criteria in Solid Tumors (RECIST) criteria were used to determine clinical efficacy. Corollary biological studies included assessment of CRAd replication, wild-type virus generation, viral shedding, and neutralizing antibody response. Results: Twenty-one patients were treated. Adverse clinical effects were limited to grade 1/2 fever, fatigue, or abdominal pain. No vector-related grade 3/4 toxicities were noted. No clinically significant laboratory abnormalities were noted. The maximum tolerated dose was not reached. Over a 1 month follow-up, 15 (71%) patients had stable disease and six (29%) had progressive disease. No partial or complete responses were noted. Seven patients had a decrease in CA-125; four had a >20% drop. RGD-specific PCR showed the presence of study vector in ascites of 16 patients. Seven revealed an increase in virus after day 3, suggesting replication of Ad5-Δ24-RGD. Minimal wild-type virus generation was detected. Viral shedding studies showed insignificant shedding in the serum, saliva, and urine. Anti-adenoviral neutralizing antibody effects were prevalent. Conclusions: This study, the first to evaluate an infectivity-enhanced CRAd in human cancer, shows the feasibility, safety, potential antitumor response, and biological activity of this approach in ovarian cancer. Further evaluation of infectivity enhanced virotherapy approaches for malignant gynecologic diseases is warranted. Clin Cancer Res; 16(21); 5277–87. ©2010 AACR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WQ完成签到,获得积分10
1秒前
Fin2046完成签到,获得积分10
3秒前
3秒前
所所的应助被科研通管家采纳,获得10
4秒前
科研通AI65的应助被科研通管家采纳,获得10
4秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
4秒前
Akim的应助被科研通管家采纳,获得10
4秒前
李健的应助被科研通管家采纳,获得10
4秒前
脑洞疼的应助被科研通管家采纳,获得10
4秒前
Dr.Joseph完成签到,获得积分10
6秒前
zsm关注了科研通微信公众号
8秒前
magic完成签到,获得积分10
12秒前
diyyid完成签到,获得积分10
13秒前
13秒前
千仞发布了新的文献求助10
16秒前
BIBIYU完成签到,获得积分10
18秒前
润run发布了新的文献求助10
19秒前
段棋晔发布了新的文献求助10
20秒前
22秒前
挚友发布了新的文献求助10
22秒前
Hello的应助被机智的青易采纳,获得10
23秒前
精明尔柳完成签到,获得积分10
24秒前
szxa发布了新的文献求助10
25秒前
25秒前
27秒前
once发布了新的文献求助30
28秒前
28秒前
充电宝的应助被刻苦乐天采纳,获得10
28秒前
28秒前
29秒前
永日安宁完成签到,获得积分10
31秒前
傅jh发布了新的文献求助10
31秒前
kali发布了新的文献求助10
34秒前
丘比特的应助被moriaty采纳,获得20
35秒前
36秒前
研友_VZG7GZ的应助被dyler采纳,获得10
36秒前
37秒前
顾矜的应助被szxa采纳,获得10
38秒前
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184932
求助须知:如何正确求助?哪些是违规求助? 9573870
关于积分的说明 21833572
捐赠科研通 7782362
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558650
邀请新用户注册赠送积分活动 2481161